Pancreatic cancer serum biomarker PC-594: Diagnostic performance and comparison to CA19-9
Shawn A Ritchie, Bassirou Chitou, Dushmanthi Jayasinghe, Department of Biomarker Discovery and Validation, Phenomenome Discoveries, Saskatoon, SK S7N 4L8, Canada
Qingan Zheng, Department of Manufacturing, Phenomenome Discoveries, Saskatoon, SK S7N 4L8, Canada
Wei Jin, Asuka Mochizuki, Phenomenome Laboratory Services, Saskatoon, SK S7N 4L8, Canada
Dayan B Goodenowe, Phenomenome Discoveries, Saskatoon, SK S7N 4L8, Canada
Author contributions: Ritchie SA and Goodenowe DB designed the studies and directed the research; Ritchie SA was the primary author, directed the CA19.9 analysis, and analyzed all data; Chitou B performed, reviewed and verified the statistical analyses; Zheng Q and Jayasinghe D performed PC-594 isolation; Jin W and Mochizuki A developed the tandem MS assay and performed the analysis.
Ethics approval: All human biospecimens distributed by Conversant Bio (601 Genome Way Suite 1200, Huntsville, Alabama 35806) were collected, processed, and distributed in full ethical and regulatory compliance with the Sites from which human biospecimens are collected. This includes independent ethical review, Institutional Review Board approval (where appropriate), independent regulatory review, and Conversant Bio ethical review for all of Conversant Bio’s collection Sites. All tissues were obtained within applicable laws.
Informed consent: Samples for this study were obtained commercially from Conversant Bio (601 Genome Way Suite 1200, Huntsville, Alabama 35806). Conversant Bio warrants that a separate patient consent form containing language substantially the same as that which is set forth in the consent form was signed by each patient from whom recipient party received human biospecimens. All patients signed informed consents, and samples were collected under ethics-approved protocols according to the requirements of Conversant Bio.
Conflict-of-interest: All authors of this work received salaries from Phenomenome Discoveries, Inc. during the duration of the project. Dayan Goodenowe is a shareholder of Phenomenome Discoveries, Inc. Shawn Ritchie is listed as inventor relating to the use of PC-594 for identifying pancreatic cancer risk, PCT/CA/2010/001565.
Data sharing: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Shawn A Ritchie, Department of Biomarker Discovery and Validation, Phenomenome Discoveries, Inc. 204-407 Downey Road, Saskatoon, SK S7N 4L8, Canada. email@example.com
Telephone: +1-306-2448233 Fax: +1-306-2446730
Received: January 7, 2015
Peer-review started: January 8, 2015
First decision: January 22, 2015
Revised: February 11, 2015
Accepted: March 19, 2015
Article in press: March 19, 2015
Published online: June 7, 2015